181 related articles for article (PubMed ID: 22148836)
1. Cyclostreptin derivatives specifically target cellular tubulin and further map the paclitaxel site.
Calvo E; Barasoain I; Matesanz R; Pera B; Camafeita E; Pineda O; Hamel E; Vanderwal CD; Andreu JM; López JA; Díaz JF
Biochemistry; 2012 Jan; 51(1):329-41. PubMed ID: 22148836
[TBL] [Abstract][Full Text] [Related]
2. Cyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites.
Buey RM; Calvo E; Barasoain I; Pineda O; Edler MC; Matesanz R; Cerezo G; Vanderwal CD; Day BW; Sorensen EJ; López JA; Andreu JM; Hamel E; Díaz JF
Nat Chem Biol; 2007 Feb; 3(2):117-25. PubMed ID: 17206139
[TBL] [Abstract][Full Text] [Related]
3. Cyclostreptin (FR182877), an antitumor tubulin-polymerizing agent deficient in enhancing tubulin assembly despite its high affinity for the taxoid site.
Edler MC; Buey RM; Gussio R; Marcus AI; Vanderwal CD; Sorensen EJ; Díaz JF; Giannakakou P; Hamel E
Biochemistry; 2005 Aug; 44(34):11525-38. PubMed ID: 16114889
[TBL] [Abstract][Full Text] [Related]
4. Interaction of a cyclostreptin analogue with the microtubule taxoid site: the covalent reaction rapidly follows binding.
Bai R; Vanderwal CD; Díaz JF; Hamel E
J Nat Prod; 2008 Mar; 71(3):370-4. PubMed ID: 18298077
[TBL] [Abstract][Full Text] [Related]
5. Cyclostreptin and microtubules: is a low-affinity binding site required?
Prussia AJ; Yang Y; Geballe MT; Snyder JP
Chembiochem; 2010 Jan; 11(1):101-9. PubMed ID: 19946930
[TBL] [Abstract][Full Text] [Related]
6. Taccalonolide binding to tubulin imparts microtubule stability and potent in vivo activity.
Risinger AL; Li J; Bennett MJ; Rohena CC; Peng J; Schriemer DC; Mooberry SL
Cancer Res; 2013 Nov; 73(22):6780-92. PubMed ID: 24048820
[TBL] [Abstract][Full Text] [Related]
7. Crystal Structure of the Cyclostreptin-Tubulin Adduct: Implications for Tubulin Activation by Taxane-Site Ligands.
Balaguer FA; Mühlethaler T; Estévez-Gallego J; Calvo E; Giménez-Abián JF; Risinger AL; Sorensen EJ; Vanderwal CD; Altmann KH; Mooberry SL; Steinmetz MO; Oliva MÁ; Prota AE; Díaz JF
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30897704
[TBL] [Abstract][Full Text] [Related]
8. Zampanolide, a potent new microtubule-stabilizing agent, covalently reacts with the taxane luminal site in tubulin α,β-heterodimers and microtubules.
Field JJ; Pera B; Calvo E; Canales A; Zurwerra D; Trigili C; Rodríguez-Salarichs J; Matesanz R; Kanakkanthara A; Wakefield SJ; Singh AJ; Jiménez-Barbero J; Northcote P; Miller JH; López JA; Hamel E; Barasoain I; Altmann KH; Díaz JF
Chem Biol; 2012 Jun; 19(6):686-98. PubMed ID: 22726683
[TBL] [Abstract][Full Text] [Related]
9. Distinct pose of discodermolide in taxol binding pocket drives a complementary mode of microtubule stabilization.
Khrapunovich-Baine M; Menon V; Verdier-Pinard P; Smith AB; Angeletti RH; Fiser A; Horwitz SB; Xiao H
Biochemistry; 2009 Dec; 48(49):11664-77. PubMed ID: 19863156
[TBL] [Abstract][Full Text] [Related]
10. Insights into the interaction of discodermolide and docetaxel with tubulin. Mapping the binding sites of microtubule-stabilizing agents by using an integrated NMR and computational approach.
Canales A; Rodríguez-Salarichs J; Trigili C; Nieto L; Coderch C; Andreu JM; Paterson I; Jiménez-Barbero J; Díaz JF
ACS Chem Biol; 2011 Aug; 6(8):789-99. PubMed ID: 21539341
[TBL] [Abstract][Full Text] [Related]
11. The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization.
Prota AE; Danel F; Bachmann F; Bargsten K; Buey RM; Pohlmann J; Reinelt S; Lane H; Steinmetz MO
J Mol Biol; 2014 Apr; 426(8):1848-60. PubMed ID: 24530796
[TBL] [Abstract][Full Text] [Related]
12. Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance.
Aoyama A; Katayama R; Oh-Hara T; Sato S; Okuno Y; Fujita N
Mol Cancer Ther; 2014 Dec; 13(12):2978-90. PubMed ID: 25313010
[TBL] [Abstract][Full Text] [Related]
13. A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity.
Du T; Lin S; Ji M; Xue N; Liu Y; Zhang Z; Zhang K; Zhang J; Zhang Y; Wang Q; Sheng L; Li Y; Lu D; Chen X; Xu H
Cancer Lett; 2020 Dec; 495():22-32. PubMed ID: 32931884
[TBL] [Abstract][Full Text] [Related]
14. Dissecting paclitaxel-microtubule association: quantitative assessment of the 2'-OH group.
Sharma S; Lagisetti C; Poliks B; Coates RM; Kingston DG; Bane S
Biochemistry; 2013 Apr; 52(13):2328-36. PubMed ID: 23473345
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis for class V beta-tubulin effects on microtubule assembly and paclitaxel resistance.
Bhattacharya R; Cabral F
J Biol Chem; 2009 May; 284(19):13023-32. PubMed ID: 19282281
[TBL] [Abstract][Full Text] [Related]
16. The microtubule-pore gatekeeper.
Snyder JP
Nat Chem Biol; 2007 Feb; 3(2):81-2. PubMed ID: 17235340
[No Abstract] [Full Text] [Related]
17. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.
Tangutur AD; Kumar D; Krishna KV; Kantevari S
Curr Top Med Chem; 2017; 17(22):2523-2537. PubMed ID: 28056738
[TBL] [Abstract][Full Text] [Related]
18. The compound millepachine and its derivatives inhibit tubulin polymerization by irreversibly binding to the colchicine-binding site in β-tubulin.
Yang J; Yan W; Yu Y; Wang Y; Yang T; Xue L; Yuan X; Long C; Liu Z; Chen X; Hu M; Zheng L; Qiu Q; Pei H; Li D; Wang F; Bai P; Wen J; Ye H; Chen L
J Biol Chem; 2018 Jun; 293(24):9461-9472. PubMed ID: 29691282
[TBL] [Abstract][Full Text] [Related]
19. βI-tubulin mutations in the laulimalide/peloruside binding site mediate drug sensitivity by altering drug-tubulin interactions and microtubule stability.
Kanakkanthara A; Rowe MR; Field JJ; Northcote PT; Teesdale-Spittle PH; Miller JH
Cancer Lett; 2015 Sep; 365(2):251-60. PubMed ID: 26052091
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in research of colchicine binding site inhibitors and their interaction modes with tubulin.
Sun K; Sun Z; Zhao F; Shan G; Meng Q
Future Med Chem; 2021 May; 13(9):839-858. PubMed ID: 33821673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
